FOXO Technologies Inc. (FOXO) reported a significant year-over-year increase in net revenues for the quarter ended September 30, 2024, primarily due to the acquisitions of Myrtle and RCHI. Net revenues rose to $1,196 thousand, compared to $10 thousand in the same period last year. Operating expenses decreased by 37%, with selling, general, and administrative expenses dropping by 63%. The company's net loss improved by 47%, with a net loss attributable to FOXO of $1,946 thousand. Non-operating expenses increased due to higher interest expenses. The company's liquidity position remains a concern, with a working capital deficit and total stockholders' deficit reported. FOXO continues to seek additional funding to support operations and has raised capital through various debt financings. The healthcare segment, which includes Myrtle and RCHI, contributed $1,188 thousand to net revenues, while the Labs and Life segment saw a slight decrease in revenues. The company's future performance is subject to risks including economic conditions, healthcare reforms, and the ability to attract and retain qualified healthcare professionals.

FOXO Technologies Inc. (FOXO) reported a significant year-over-year increase in net revenues for the quarter ended September 30, 2024, primarily due to the acquisitions of Myrtle and RCHI. Net revenues rose to $1,196 thousand, compared to $10 thousand in the same period last year. Operating expenses decreased by 37%, with selling, general, and administrative expenses dropping by 63%. The company's net loss improved by 47%, with a net loss attributable to FOXO of $1,946 thousand. Non-operating expenses increased due to higher interest expenses. The company's liquidity position remains a concern, with a working capital deficit and total stockholders' deficit reported. FOXO continues to seek additional funding to support operations and has raised capital through various debt financings. The healthcare segment, which includes Myrtle and RCHI, contributed $1,188 thousand to net revenues, while the Labs and Life segment saw a slight decrease in revenues. The company's future performance is subject to risks including economic conditions, healthcare reforms, and the ability to attract and retain qualified healthcare professionals.